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Impaired sensorimotor gating of the acoustic startle response in
the prodrome of schizophrenia
Abstract
BACKGROUND: Schizophrenia patients exhibit impairment in prepulse inhibition (PPI) of the acoustic
startle response (ASR), which is commonly interpreted as a sensorimotor gating deficit. To date, it is
unclear when these gating deficits arise. Results of animal studies and some human data suggest that PPI
deficits are in part genetically determined, such that gating deficits could be present before the onset of a
full-blown psychosis. To test this assumption, we investigated PPI of ASR in individuals with
prodromal symptoms of schizophrenia and patients with first-episode schizophrenia. METHODS:
Startle reactivity, habituation, and PPI of ASR, as well as a neuropsychological test battery, were
assessed in 54 subjects with prodromal symptoms of schizophrenia (35 early and 19 late prodromal
subjects), 31 first-episode schizophrenia patients (14 unmedicated, 17 medicated), and 28 healthy
control subjects. Patients were also examined with the Positive and Negative Syndrome Scale and the
Global Assessment of Functioning Scale. RESULTS: Prodromal subjects and unmedicated patients with
first-episode schizophrenia showed significant PPI deficits, whereas schizophrenia patients treated with
risperidone had almost normal PPI. Startle reactivity decreased with greater severity of symptoms
(control subjects, early prodromal group > late prodromal group > unmedicated first-episode patients)
but was almost normal in the medicated patients. With respect to habituation, prodromal subjects and
schizophrenia patients did not differ from healthy control subjects. CONCLUSIONS: PPI disruption is
already present in a prodromal state of schizophrenia, but startle reactivity deficits seem to emerge with
the onset of acute psychosis.
Impaired PPI in the prodrome of schizophrenia  Quednow et al. 
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Abstract 
 
Background: Schizophrenia patients exhibit impairment in prepulse inhibition (PPI) of the acoustic 
startle response (ASR) which is commonly interpreted as a sensorimotor gating deficit. To date, it is 
unclear when these gating deficits arise. Results of animal studies and some human data suggest that 
PPI deficits are in part genetically determined, such that gating deficits could be present before onset 
of a full-blown psychosis. To test this assumption, we investigated PPI of ASR in individuals with 
prodromal symptoms of schizophrenia and patients with first-episode schizophrenia. 
Methods: Startle reactivity, habituation, and PPI of ASR as well as a neuropsychological test battery 
were assessed in 54 subjects with prodromal symptoms of schizophrenia (35 early and 19 late 
prodromal subjects), 31 first-episode schizophrenia patients (14 unmedicated, 17 medicated), and 28 
healthy controls. Patients were also examined with the Positive and Negative Symptom Scale and the 
Global Assessment of Functioning Scale. 
Results: Prodromal subjects and unmedicated patients with first-episode schizophrenia showed 
significant PPI deficits, whereas schizophrenia patients treated with risperidone had almost normal 
PPI. Startle reactivity decreased with greater severity of symptoms (controls, early prodromal group > 
late prodromal group > unmedicated first-episode patients) but was almost normal in the medicated 
patients. With respect to habituation, prodromal subjects and schizophrenia patients did not differ from 
healthy controls. 
Conclusions: PPI disruption is already present in a prodromal state of schizophrenia but startle 
reactivity deficits seem to emerge with the onset of acute psychosis. 
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Introduction 
Since the publication of Kraepelin’s (1) and Bleuler’s (2) findings, attentional and information-
processing deficits are considered to constitute core symptoms of schizophrenia and schizophrenia 
spectrum disorders and impairments in the processing of preattentive inhibitory stimuli – also referred 
to as “sensorimotor gating” – appear to play a crucial role in the pathogenesis of schizophrenia (3-7). 
Prepulse inhibition (PPI) of the acoustic startle response (ASR) has been firmly established as an 
operational measure of sensorimotor gating (8). PPI is defined as a substantial reduction of the 
amplitude of the startle reflex that occurs when a distinctive non-startling stimulus is presented 30-500 
ms prior to the startling stimulus (9). It was proposed that the mechanism underlying PPI regulates 
sensory input by filtering out irrelevant or distracting stimuli in order to prevent sensory information 
overflow and to allow for selective and efficient processing of relevant information (10).  
Diminished PPI has been consistently demonstrated in patients with schizophrenia (8,11-15) and 
schizotypal personality disorder (11,16). The PPI deficit in schizophrenia is supposed to reflect a 
central abnormality underlying the disease; both neuroanatomical and neurochemical factors have 
been implicated on the basis of animal studies, which suggest contributions of diverse neurotransmitter 
systems, and particular functional association with multiple loci in the cortico-striato-pallido-thalamic 
(CSPT) circuitry (17,18). 
To date, it is unclear whether these gating deficits arise with or after the onset of an acute 
psychosis or if these deficits already exist before onset of schizophrenia. However, the expression of 
PPI seems subject to strong genetic influences, as evidenced by the presence of significant differences 
in PPI between inbred strains of rodents (19-21). It has been recently estimated that the heritability of 
PPI in schizophrenia patients and their families is about 32%, whereas another study reported a 
heritability of 50% within a healthy twin sample (22,23). Furthermore, sibling pairs (one with and one 
without schizophrenia) show a relatively high correlation in PPI (r=0.66) (11). Recently, quantitative 
trait loci for PPI have been identified in rodents (24-26), and studies in humans suggest that mutations 
of the neuregulin-1, the dopamine-D3 receptor, and the serotonin-2A receptor gene affects PPI (27-
29). Two studies have shown that unaffected first-degree relatives of schizophrenia patients also 
display PPI deficits, supporting the view that genetic influences also mediate PPI deficits in 
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schizophrenia (11,30). In sum, these genetic findings suggest that PPI deficits could occur already 
before onset of schizophrenia and, thus, PPI deficits may serve as simple indicator for the vulnerability 
for schizophrenia. 
To test this hypothesis, we investigated PPI, startle reactivity, and habituation of ASR in subjects 
in a prodromal state likely to proceed to schizophrenia. The study was conducted within the frame of 
the German Research Network on Schizophrenia (GRNS)(31). Given that early and late stages of 
developing psychosis could be distinguished (31-33), we examined prodromal subjects supposed to be 
either in an early or a late prodromal state of schizophrenia. Whereas the early prodromal stage 
presents self-experienced cognitive and perceptual alterations (basic symptoms) shown as predictive 
for later psychosis (34), the late prodromal stage is additionally characterized by attenuated or 
transient psychotic symptoms (31). Moreover, we studied unmedicated and medicated first-episode 
patients, since antipsychotic treatment, especially with atypical agents, can improve PPI (12,15,35-39). 
Thus, we measured PPI in five groups: early prodromal subjects (EP), late prodromal subjects (LP), 
unmedicated first-episode schizophrenia patients (US), medicated first-episode schizophrenia patients 
(MS), and healthy control subjects (HC). We assumed that the same etiological risk factors would 
underlie prodromal states and schizophrenia and we therefore hypothesized that PPI disruption would 
already be present in groups of prodromal subjects. Based on previous findings we also expected that 
PPI impairments would be less marked in MS than in US. 
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Methods and materials 
Participants 
Subjects with symptoms suggestive of either early or late prodromal stages were recruited as 
described previously (31). In brief, subjects were screened by general practitioners, counseling 
services or secondary health care providers using the 17-item Early Recognition Inventory/Interview 
for the Retrospective Assessment of the Onset of Schizophrenia (ERIraos) checklist (31). Persons 
scoring six points or higher were referred to the Early Recognition and Intervention Center at the 
Department of Psychiatry, University of Bonn, for detailed assessment with the 110-item ERIraos 
symptom list (31). 
The criteria for the early prodromal state were based 1) either on presence of basic symptoms 
which were shown as highly predictive for psychosis (34) or 2) on the presence of a first-degree 
relative with a psychotic disorder in conjunction with a reduction of the global assessment of function 
(GAF). In contrast, subjects with attenuated positive symptoms (APS) or brief limited intermittent 
psychotic symptoms (BLIPS) were considered to be in a late prodromal stage, which is in line with 
conventional criteria used in other clinical high-risk studies (40). 
Prodromal subjects and schizophrenia patients were not included if they had a diagnosis of a 
developmental disorder, an organic psychiatric disorder or a history of a neurological disorder, 
dementia or alcohol and drug abuse within the last three months prior to the study. Based on these 
criteria, we included 39 subjects in an early prodromal stage (EP) and 23 subjects at a late prodromal 
stage (LP). Two EP and two LP received treatment with atypical antipsychotics. One EP and six LP 
were treated with antidepressants. 
The group of schizophrenia inpatients included 18 unmedicated patients (US) and 17 medicated 
patients (MS), both with a first exacerbation of schizophrenia according to DSM-IV criteria. The 
medicated schizophrenia patients had been randomly and double-blind assigned to either haloperidol 
(mean dose±SD: 4.6±1.6 mg, range: 3-8 mg) or risperidone (4.5±2.4 mg, range: 2-10 mg) maintenance 
treatment, as part of a separate clinical trial, results of which are published elsewhere (41). US were 
never systematically treated with antipsychotics before and none of them took an antidepressant for at 
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least four weeks. Two MS were also treated with antidepressants. Benzodiazepine treatment was 
discontinued 24 hours before ASR assessment.  
Finally, 32 healthy control subjects were matched with respect to age, sex and education to the 
prodromal subjects. These volunteers were recruited by advertising in local newspapers, word of 
mouth or they were actively contacted by the investigators based on their listing as community 
residents. None had past or present psychiatric, neurological, or somatic disorder, and negate use of 
psychotropic medication or illicit drug use. Moreover, none of the control subjects reported a family 
history of psychiatric disorders.  
This study was approved by the Ethics Committee of the Medical Faculty of the University of 
Bonn. After receiving a written and oral description of the aim of this study, all participants gave 
written informed consent statements before inclusion.  
 
Clinical assessment 
To ensure eligibility for the study every participant was evaluated by a Structured Clinical 
Interview (SCID-I) according to DSM-IV. Clinical symptoms were measured with the Positive and 
Negative Symptom Scale (PANSS)(42). Psychosocial functioning was assessed using the Global 
Assessment of Functioning (GAF)(43). For the estimation of verbal IQ, the Mehrfachwahl-Wortschatz-
Intelligenztest (MWT-B) was used (44).  
 
Startle response measurement 
After the clinical examination, a neuropsychological test battery was administered first (these 
results will be published elsewhere), followed by the ASR assessment. Before each ASR assessment, 
all participants underwent a brief hearing test. The PPI paradigm was based on the study of Braff et al. 
(8) and has been described in detail in our previous work (15,45). In brief, subjects received 73 sound 
pulses with a power of 116 dB along with 70 dB background white noise. In 36 of the trials, the pulse 
was preceded by an 86-dB prepulse with an interstimulus interval (ISI) of 120 ms. The eye-blink 
component of the ASR was measured using an electromyographic startle system (San Diego 
Instruments, San Diego, CA). To ensure that PPI was not influenced by smoking withdrawal, smoking 
ad libitum was permitted before testing (46). Error trials were defined as trials in which no startle 
response was recorded because of a baseline shift normally due to spontaneous or voluntary blinks 
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(8,45). Four healthy subjects (12.5%), eight prodromal subjects (12.9%) and four schizophrenia 
patients (11.4%) with error trials greater than 50% were excluded from data analysis.  
 
Statistical analysis 
The mean percent PPI of startle amplitude was calculated using the formula: 
%PPI=100×(magnitude on pulse alone (PA) trials–magnitude on prepulse (PP) trials)/magnitude on 
PA trials (8). PA trials were divided into six blocks, each comprising six trials. Startle reactivity was 
assessed by calculating the mean amplitude of the first block of PA trials. To assess habituation, the 
linear gradient coefficient b was calculated across the six blocks of PA by the following formula: 
b=(nΣxy–(Σx)(Σy))/(nΣx2–(Σx)2), where x=block number, y=startle amplitude of PA trials per block 
(47). All data were analyzed using SPSS 12.0 for Windows. Because all dependent variables were 
normally distributed, the demographic, clinical and startle data were analyzed by analysis of variance. 
Given that gender, smoking, and age could have an impact on startle parameters (46,48-50), these 
demographic variables were introduced as covariates in analyses of covariance (ANCOVA). Based on 
significant main effects, Least Significant Difference (LSD) post-hoc comparisons were performed. 
Demographic frequency data were analyzed using Chi2 -tests. Interrelationships between startle 
measurements and clinical or demographic data were tested using Pearson’s product-moment-
correlation. The confirmatory statistical comparisons were carried out at a significance level set at 
p<.05 (2-tailed). Within the correlation analyses, the significance level was set at p<.01 (2-tailed) in 
order to avoid accumulation of α-error. Finally, effect sizes were calculated with GPOWER (51). 
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Results 
Demographic data and clinical data 
Demographic data and clinical data are shown in Table 1. Multiple and single comparisons with 
Chi2-tests revealed no significant differences with respect to gender and smoking, and ANOVA 
showed no significant differences with respect to years of education or verbal IQ between the groups. 
However, an ANOVA revealed a significant group effect for age [p<.01]. LSD post-hoc tests showed 
that both EP and LP were younger than US [p<.05] and MS [p<.01]. However, the mean age of HC 
did not differ from the other groups.  
Although it was previously reported that age has an effect on startle magnitude and habituation, 
but not on PPI (49), we could not demonstrate any significant correlation between age and startle 
parameters within the total sample. Within subgroups, we found only a trend for correlations between 
PPI, startle reactivity and age in MS [r=-.55, p=.02; r=-.54, p=.02] indicating lower PPI and startle 
reactivity in older patients. However, we introduced age as a covariate in the analysis of startle data. 
Analyses of the PANSS scores revealed significant group effects for all PANSS scores [p<.001]. 
LSD post-hoc tests revealed that EP had significantly lower positive [p<.01; p<.001], negative 
[p<.001], global [p<.05; p<.001], and total symptoms [p<.01; p<.001] than LP and US, whereas LP 
had significantly lower values in all of these scores than did US [p<.001]. Compared to US, the MS 
group showed significantly improved positive [p<.001], negative [p<.01], global [p<.001], and total 
symptoms [p<.001]. Furthermore, EP and LP showed significantly lower negative symptoms than did 
MS [p<.001; p<.05]. EP showed also a significantly lower total score than did MS [p<.01]. 
Analysis of the GAF scores revealed also a significant group effect [p<.001]. US had significantly 
worse psychosocial functioning than did EP, LP, and MS [p<.001]. Finally, MS exhibited a 
significantly better GAF score than did EP [p<.01]. 
 
****Insert Table 1**** 
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PPI 
An ANCOVA (with age, gender, and smoking as covariates) revealed a significant group-effect 
with respect to %PPI [F(4,105)=4.1, p<.01]. LSD post-hoc tests showed that EP [p<.01, d=.74], LP 
[p<.01, d=.92], and US [p<.05, d=.69] had a decreased PPI as compared to HC, whereas MS did not 
differ from HC [p=.21, d=.38] (see Figure 1). The effects of age, smoking, and gender were not 
significant. Using a conservative clinical cut-off score, 26% of the EP, 37% of the LP, 36% of the US, 
and 18% of the MS had a PPI value lower than two standard deviations (SD) from the mean of the 
HC. When a one SD threshold is applied, 49% of the EP, 53% of LP, 50% of the US, and 30% of the 
MS did show abnormal PPI. 
 
****Insert Figure 1**** 
 
Startle reactivity and habituation 
An ANCOVA of the mean amplitude of pulse-alone trials (with age, gender, and smoking as 
covariates) showed that the groups significantly differed with respect to startle reactivity 
[F(4,105)=2.5, p<.05]. LSD post-hoc tests revealed a decreased startle amplitude in US compared to 
HC [p=.05, d=.60]. Moreover, US [p<.01, d=.92] and LP [p<.05, d=.61] showed a significant lower 
startle reactivity than did EP (see Figure 2). The effects of age, smoking, and gender did not reach 
significance level. 
An ANCOVA (with age, gender, and smoking as covariates) of the linear gradient coefficient b 
did not show a significant group effect with respect to habituation [F(4,105)=1.8, p=.13] (see Figure 
3). The effects of the covariates were also not significant. 
 
****Insert Figure 2**** 
****Insert Figure 3**** 
 
Exploratory analyses 
An analysis of the ERIraos checklist at item level revealed that %PPI was significantly decreased 
in prodromal subjects reporting a history of perinatal complications (yes: 20.8%) [F(1,52)=6.9, p<.01, 
d=.85], or in prodromal subjects showing thought-blocking (49%) [F(1,52)=4.8, p<.05, d=.58], 
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delusion of jealousy (5.7%) [F(1,52)=12.0, p<.001, d=1.87], auditory hallucinations (5.7%) 
[F(1,52)=11.0, p<.01, d=1.80], olfactory and gustatory hallucinations (5.7%) [F(1,52)=4.3, p<.05, 
d=1.20], and somatic and tactile hallucinations (7.5%) [F(1,52)=4.5, p<.05, d=1.07] compared to 
prodromal subjects without those symptoms.  
 
Previous studies reported different effects of typical and atypical antipsychotics on PPI 
(12,35,36,38,39). We therefore analyzed possible differences between the schizophrenia patients 
randomly treated with either haloperidol or risperidone (see Figure 4). In an ANOVA with the HC, the 
haloperidol-treated MS, and the risperidone-treated MS, there was a main group-effect on %PPI 
[F(2,42)=3.1, p<.05]. Haloperidol-treated MS had a significant lower %PPI as compared to HC 
[p<.05, d=.89]. Additionally, there was a trend for a lower %PPI of the haloperidol treated MS 
compared to the risperidone-treated schizophrenia patients [p<.07, d=.86], whereas risperidone-treated 
subjects did not differ from HC [p=.93, d=.04]. There were no significant differences with respect to 
startle reactivity and habituation between haloperidol- and risperidone-treated MS. 
 
During the follow-up observation period of 12 month, eight prodromal subjects (14.8%) transited 
into full-blown psychosis (three EP, five LP). Within the same period, two EP (5.7%) transited into the 
LP state. With respect to PPI, transited prodromal subjects (mean %PPI: 36.0, SEM: ±7.7) did not 
differ from non-transited prodromal subjects (35.6±4.8). Both groups also did not differ with respect 
to startle reactivity and habituation.  
 
****Insert Figure 4**** 
 
Correlations between startle measurement and clinical data 
%PPI, startle reactivity and habituation did not significantly correlate with verbal IQ, years of 
education, smoking, gender or psychopathological scales neither across all groups, nor within the 
groups. 
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Discussion 
The present study is the first to investigate PPI, habituation and startle reactivity of the ASR in 
individuals fulfilling research diagnostic criteria of a psychotic prodrome. The major finding is that 
prodromal subjects had a significant PPI deficit. This was true for both early and late prodromal 
subgroups. As expected, we could also demonstrate reduced PPI in unmedicated first-episode 
schizophrenia patients, whereas medicated schizophrenia patients did not differ from controls. Further 
analysis revealed that the risperidone-treated patients had almost normal PPI, while the haloperidol-
treated patients had a considerable attenuation of PPI.  
These results strongly suggest that PPI deficits are present well before the onset of full-blown 
psychosis and that they are stable vulnerability-markers rather than state-dependent symptoms of 
schizophrenia. At first glance it may be somewhat surprising that the PPI deficit of prodromal subjects 
was comparable to that seen in unmedicated patients with first-episode schizophrenia because there 
are certainly some “false positives” within the prodromal group who will never proceed to psychosis. 
This could be explained by two reasons: First, about 15% of the prodromal subjects went on to 
develop psychosis during the brief 12-month follow-up interval but PPI scores of prodromal subjects 
subsequently transiting to psychosis did not differ from non-transited prodromal subjects. However, 
the expected long-term conversion rate of our prodromal subjects is much higher. Klosterkötter et al. 
have shown that 70% of the prodromal subjects, which were selected by similar criteria as the early 
prodromal subjects in the present study, transited to psychosis within 10 years (34). Long-term 
observations of ultra-high risk/late prodromal subjects are not available so far but the North American 
Prodrome Longitudinal Study (NAPLS) recently reported a transition rate of 35% within 2 ½ years 
(32). It is therefore premature to draw firm conclusions about the predictive validity of PPI because 
our follow-up period was too brief to detect all “true” prodromal subjects. Second, both the putative 
prodromal state and schizophrenia are characterized by information processing deficits and these 
deficits may be reflected by PPI reductions irrespective of later transition. The fact that PPI is 
markedly reduced in schizotypal personality disorder suggests that PPI is more related to symptoms of 
the schizophrenia spectrum in general rather than exclusively to full-blown psychosis (11,16). Thus, 
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we propose that PPI deficits capture an aspect of the trait-like vulnerability for psychosis, and this 
vulnerability can be inferred from family history, schizotypal or prodromal symptoms alike.  
Moreover, the present data also validate the psychopathological approach for identifying high-
risk subjects, given that a considerable proportion of the prodromal subjects with impaired PPI 
progressed to psychosis. The fact that high-risk subjects with an early prodrome also have a PPI 
deficits supports the inclusion of basic symptoms in recent European early detection studies (31,52). 
For late prodromal subjects, a growing body of literature suggests that structural and functional 
brain alterations precede the onset of psychosis (53-55). Our finding of reduced PPI in late prodromal 
subjects is consistent with structural MRI findings of reduced grey matter volume in ultra-high-risk 
subjects for psychosis in several brain regions also implicated in PPI, i.e. hippocampus, basal ganglia, 
inferior frontal gyrus and superior temporal gyrus (56,57). Moreover, our data imply that early 
prodromal subjects already suffer from perturbation in the cortico-striato-pallido-thalamic (CSPT) 
circuitry which has been shown as responsible for processing PPI (17,58). In contrast, mediotemporal 
structural changes only became evident after the onset of a psychotic illness, which furthermore gave 
rise to the hypothesis that CSPT-changes occur prior to the onset of discernible mediotemporal lobe 
structural alterations (59).  
 
In exploratory analyses, we found that PPI was particularly reduced in prodromal subjects 
reporting the negative symptom thought blocking or transient positive symptoms (BLIPS), especially 
delusion of jealousy or diverse types of hallucinations. This is in line with previous studies reporting 
that PPI deficits in schizophrenia are correlated with thought disorder (60-62) or with global scales of 
positive symptoms (63-65). The frequently replicated association of PPI with psychopathological 
symptoms of psychosis is consistent with the hypothesis that the impaired sensorimotor gating 
processes contribute to these symptoms (66). Interestingly, we also found that PPI was especially 
reduced in the prodromal subjects with suspected perinatal complications. This is in agreement with 
the finding that early developmental insults can contribute to the diathesis for schizophrenia (67). In 
addition, neurodevelopmental animal models of schizophrenia have shown that neonatal lesions of the 
hippocampus cause PPI disruption (68,69). 
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Although sample sizes were small, our present finding that only haloperidol-treated schizophrenia 
patients but not risperidone-treated patients showed a PPI deficit is in agreement with results of some 
earlier clinical studies (39,57). With respect to the underlying mechanisms, Kumari et al. concluded 
from their fMRI investigation that atypical substances maybe more effective in restoring activity in 
PPI-relevant regions than typical antipsychotics (57). Nevertheless, whether antipsychotic agents 
could reverse PPI deficits in schizophrenia is still subject of debate (35).  
The present data illustrate a seeming discrepancy of two sets of PPI findings related to 
schizophrenia. First, the PPI deficit appears to be a stable trait marker, likely genetically influenced, 
and observed in high-risk populations such as family members or prodromal subjects. Second, PPI is a 
sensitive state marker of drug treatment in preclinical animal experiments and in several patient 
studies (as also shown here). This discrepancy is resolved when considering PPI to reflect the 
functional state of a basal sensorimotor gating system that may not be optimally “tuned” because of 
genetic or developmental reasons in schizophrenia. However, the function of this system can be 
normalized by (atypical) antipsychotics. Hence, PPI can be studied as an endophenotype to identify 
and characterize schizophrenia genes, but can also be investigated as a (state) biomarker of drug 
response. 
 
In contrast to PPI, reduced startle reactivity seems to be an episodic indicator of psychosis, 
because we found that startle reactivity decreased progressively with increasing severity of symptoms, 
on an axis proceeding from early prodrome, through late prodrome, to full-blown psychosis. This 
finding is in line with our previous report that startle reactivity is significantly decreased in 
schizophrenia patients (15). Startle reactivity was improved by treatment with typical and atypical 
antipsychotics, in agreement with our previous report (15). Since there was no statistical significance 
between the haloperidol and risperidone group, this further indicates that different mechanisms 
underlie PPI and startle reactivity. Consistent with several previous findings, we did not find a 
significant habituation deficit in schizophrenia patients (8,11,12,39). Some of the discrepant reports 
regarding habituation deficits in schizophrenia might be due to subtle deficits in startle reactivity 
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(13,47,60), which we found to be strongly correlated with habituation in the present sample [r=-.59, 
p<.0001] and in an earlier report of our laboratory (15). 
 
The present study has some limitations. First, we have not assessed urine toxicology screenings in 
our participants. However, we consider it unlikely that undetected illegal substance use has influenced 
the results. Prodromal subjects turned to our hospital because of suffering from symptoms. Those 
reporting substance abuse were not included into the study but still received proper treatment, and thus 
prodromal subjects had no reason for deception. Second, in contrast to some previous studies (48,70), 
we did not detect an effect of smoking on PPI in our sample possibly for two reasons: a) Smoking 
withdrawal can decrease PPI (46,71), but our subjects were allowed to smoke ad libitum before 
testing. b) Especially heavy smokers with schizophrenia display higher PPI levels than light- or non-
smoking patients (70) which is in line with the finding, that nicotine itself could enhance PPI (72,73). 
We did not assess severity of smoking behavior, and thus, the effect of smoking status alone was 
possibly too small to detect in our sample. Moreover, the criteria of the schizophrenia prodrome are 
still evolving. Our operational definitions for identification of subjects in a putatively prodromal state 
should not be taken as final even though the PPI data provide some neurobiological validation. 
Finally, on average, the prodromal subjects and the first-episode schizophrenia patients were older 
than in other studies probably for two reasons. First, administrative constrains required that all 
participants were 18 years or older. Thus, a large segment of the age distribution was cut. Second, it 
turned out that many prodromal subjects fulfilling the inclusion criteria were referred by secondary 
health care specialist, such as psychotherapists and psychiatrist, suggesting that they already suffered 
from symptoms already for a period of time. The observed age differences between prodromal 
subjects and schizophrenic patients are to be expected because the occurrence of prodromal symptoms 
precedes the first diagnosis of schizophrenia by several years (31). 
 
Our study provides first evidence that a sensorimotor gating deficit is already present in the 
prodrome of schizophrenia, indicating that early attentional processes are defective prior to the transit 
to full-blown psychosis. The deficit was as pronounced as among first-episode schizophrenia patients. 
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In agreement with genetic high-risk studies, our results may indicate that impaired sensorimotor gating 
could serve as trait-marker of schizophrenia. If the present findings could be replicated, PPI 
assessment may validate and improve psychopathological risk assessment and early recognition of 
schizophrenia. The strategy of using experimentally-validated electrophysiological endophenotypes 
such as PPI or P50 suppression, and concomitant genetic analyses for research of subjects at high-risk 
could permit preclinical studies to better elucidate the neurobiological basis of risk of developing 
schizophrenia, and guide the testing of early intervention strategies with animal models (74). With 
respect to this aim, the homology of PPI across species presents an important advantage over other 
putative trait-markers of schizophrenia. Longitudinal assessment of prodromal individuals with 
sensorimotor gating paradigms should clarify the merit of these measures for reliable prediction of the 
onset of schizophrenia. 
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Figure legends 
 
Figure 1: Prepulse inhibition (PPI) of acoustic startle response of early prodromal subjects (EP), late 
prodromal subjects (LP), unmedicated first-episode schizophrenic patients (US), medicated first-
episode schizophrenic patients (MS), and healthy control subjects (HC) (means and standard error of 
means). Prodromal subjects and unmedicated schizophrenic patients display a PPI deficit, whereas 
medicated schizophrenic patients showed improved PPI (LSD post-hoc tests (corrected for age, 
gender, and smoking): comparisons vs. HC: *p<.05, **p<.01). 
 
Figure 2: Startle reactivity (mean amplitude of the first block of 116-dB pulse-alone trials) of early 
prodromal subjects (EP), late prodromal subjects (LP), unmedicated first-episode schizophrenic 
patients (US), medicated first-episode schizophrenic patients (MS), and healthy control subjects (HC) 
(means and standard error of means). Only unmedicated schizophrenic patients revealed significantly 
diminished startle reactivity. However, startle reactivity decreases with presumed increase of 
proximity to the onset of the illness within prodromal subjects (LSD post-hoc tests (corrected for age, 
gender, and smoking): comparisons vs. HC: *p<.05; comparisons vs. EP: #p<.05, ##p<.01). 
 
Figure 3: Habituation of acoustic startle response (linear gradient coefficient b across six blocks of 
pulse alone trials) of early prodromal subjects (EP), late prodromal subjects (LP), unmedicated first-
episode schizophrenic patients (US), medicated first-episode schizophrenic patients (MS), and healthy 
control subjects (HC) (means and standard error of means). Although US displayed lowered 
habituation, the groups did not significantly differ with respect to habituation. 
 
Figure 4: Prepulse inhibition (PPI) of first-episode patients with schizophrenia who were randomly 
assigned to receive haloperidol (HAL) or risperidone (RISP) and healthy controls (HC) (means and 
standard error of means). Haloperidol treated patients still have a PPI deficit, whereas patients treated 
with risperidone showed normal levels of PPI compared to HC (LSD post-hoc tests: comparisons vs. 
HC: *p<.05; comparisons vs. RISP: † p=.07. 
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Table 1 Demographic and clinical characteristics of prodromal subjects, first-episode schizophrenic patients and healthy controls (means and standard 
deviation of means in parentheses; sex and smoking in frequency data). 
 
 
  Prodromal subjects  First-episode schizophrenia patients    
 Healthy controls
(HC) 
Early prodrome
(EP) 
Late prodrome 
(LP) 
 
Unmedicated 
(US) 
Medicated 
(MS) 
F/Chi2 df/dferr p 
N 28 35 19  14 17    
Age 30.5 (10.6) 27.1 (6.6) 26.2 (8.3)  33.8 (8.5) 35.5 (12.4) 3.81 4/108 <.01a 
Men in percent 57.1 65.7 63.2  57.1 70.6 1.15 4 .89 
Years of education 14.3 (2.5) 15.6 (3.0) 14.7 (3.2)  14.8 (2.7) 13.8 (2.9) 1.33 4/108 .26 
Estimated verbal IQ 105.7 (11.8) 105.3 (14.1) 102.6 (14.1)  105.2 (11.3) 110.5 (17.7) 1.10 4/108 .36 
Smoker in percent 35.7 32.3 44.4  53.8 36.4 2.18 4 .70 
PANSS Positive - 8.8 (2.0) 12.8 (4.3)  22.6 (7.9) 10.6 (3.7) 33.5 3/79 <.001b 
PANSS Negative - 9.8 (3.3) 15.1 (3.1)  24.4 (7.9) 18.9 (6.5) 29.4 3/79 <.001c 
PANSS General - 27.5 (6.6) 32.3 (5.7)  46.1 (11.7) 28.6 (8.7) 18.8 3/79 <.001d 
PANSS Total - 46.1 (8.4) 60.1 (11.2)  93.1 (24.8) 58.2 (17.0) 32.1 3/79 <.001e 
GAF Score - 57.0 (9.4) 60.2 (13.6)  34.9 (12.2) 66.2 (10.7) 13.2 3/79 <.001f 
a LSD post-hoc tests: MS > EP, LP: p<.01; US > EP, LP: p<.05 
b LSD post-hoc tests: US > EP, LP, MS: p<.001; LP > EP: p<.01 
c LSD post-hoc tests: EP < LP, MS, US: p<.001; LP < US: p<.001; LP < MS: p<.05; MS < US: p<.01 
d LSD post-hoc tests: US > EP, LP, MS: p<.001; LP > EP: p<.05 
e LSD post-hoc tests: US > EP, LP, MS: p<.001; EP < LP, MS: p<.01 
f LSD post-hoc tests: US < EP, LP, MS: p<.001; EP < MS: p<.01 
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